ITCC pediatric preclinical POC platform


Start Date
End Date
Grant agreement number

IMI Funding
7 370 000
EFPIA in kind
8 450 094
742 736
Total Cost16 562 830


Today, 20% of childhood cancers remain incurable and cancer kills 6 000 young people in Europe every year, making it the leading cause of disease-related death in the under-19s. Moreover, two thirds of those who survive a cancer in childhood experience long-term side effects as a result of their treatment. The challenge for scientists seeking to develop new treatments is the lack of tools to study childhood cancers, which are quite different in nature to most cancers found in adults.

The ITCC-P4 project will develop a large-scale platform comprising 400 novel research tools based on cells and tissues from patients covering 10 common childhood cancers, including neuroblastoma, high grade glioma, and osteosarcoma. The tools will allow researchers to explore the biology of paediatric cancers, identify sub-groups of patients that might respond better to certain treatments, and carry out tests on potential drugs.

Ultimately, the platform should significantly add to our understanding of childhood cancers and speed up the development of new treatments.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Charles River research services Germany GmbH, Freiburg, Germany
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Pharmamar, S.A., Colmenar Viejo, Spain
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, Netherlands
  • Alleanza Contro il Cancro, Roma, Italy
  • Charité – Universitätsmedizin Berlin, Berlin, Germany
  • Deutsches Krebsforschungszentrum, Heidelberg, Germany
  • Fundació Sant Joan de Deu, Esplugues de Llobregat, Spain
  • Innovative therapies for children with cancer, Villejuif, France
  • Institut Curie, Paris, France
  • Institut Gustave Roussy, Villejuif, France
  • Institute of Cancer Research - Royal Cancer Hospital, London, United Kingdom
  • Medizinische Universitaet Wien, Vienna, Austria
  • Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands
  • St. Anna Kinderkrebsforschung, Vienna, Austria
  • Universitaet Zuerich, Zürich, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Experimental Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany
  • XenTech SAS, Evry, France
Third parties
  • Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy
  • Gustave Roussy Transfert, Villejuif, France
  • Istituto Ortopedico Rizzoli , Bologna, Italy
  • Ospedale Pediatrico Bambino Gesù, Rome, Italy


Project coordinator
Stefan Pfister
Deutsches Krebsforschungszentrum
Project leader
Louis Stancato
Eli Lilly and Company